AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in patients with Advanced Solid Malignancies

Study identifier:D1532C00005

ClinicalTrials.gov identifier:NCT00463814

EudraCT identifier:2006-004497-26

CTIS identifier:2022-500685-10-00

Recruitment Complete

Official Title

A Phase I, Open Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (capsule) of AZD6244 in patients with Advanced Solid Malignancies

Medical condition

Tumor

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD6244

Sex

All

Actual Enrollment

58

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 08 Mar 2007
Primary Completion Date: 17 Jun 2008
Estimated Study Completion Date: 31 Dec 2024

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria